What determines the molecular composition of abnormal protein aggregates in neurodegenerative disease?

48Citations
Citations of this article
61Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Abnormal protein aggregates, in the form of either extracellular plaques or intracellular inclusions, are an important pathological feature of the majority of neurodegenerative disorders. The major molecular constituents of these lesions, viz., β-amyloid (Aβ), tau, and α-synuclein, have played a defining role in the diagnosis and classification of disease and in studies of pathogenesis. The molecular composition of a protein aggregate, however, is often complex and could be the direct or indirect consequence of a pathogenic gene mutation, be the result of cell degeneration, or reflect the acquisition of new substances by diffusion and molecular binding to existing proteins. This review examines the molecular composition of the major protein aggregates found in the neurodegenerative diseases including the Aβ and prion protein (PrP) plaques found in Alzheimer's disease (AD) and prion disease, respectively, and the cellular inclusions found in the tauopathies and synucleinopathies. The data suggest that the molecular constituents of a protein aggregate do not directly cause cell death but are largely the consequence of cell degeneration or are acquired during the disease process. These findings are discussed in relation to diagnosis and to studies of to disease pathogenesis. © 2008 Japanese Society of Neuropathology.

Cite

CITATION STYLE

APA

Armstrong, R. A., Lantos, P. L., & Cairns, N. J. (2008, August). What determines the molecular composition of abnormal protein aggregates in neurodegenerative disease? Neuropathology. https://doi.org/10.1111/j.1440-1789.2008.00916.x

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free